OBJECTIVE: The Pro12Ala polymorphism of the Peroxisome Proliferator Activated Receptor g g2 (PPARg g2) gene has been inconsistently associated with body mass index variations and non-insulin-dependent diabetes mellitus (NIDDM). We investigated the impact of this polymorphism on obesity markers, lipid and glucose variables in a sample of French subjects and evaluated its possible role in the onset of NIDDM. DESIGN AND SUBJECTS: Within the framework of the WHO-MONICA project, a population study composed of 1195 subjects aged 35 ± 64 y was randomly sampled from the electoral rolls of the urban community of Lille, in northern France. Subjects receiving medical treatment for hypercholesterolemia, hypertension or diabetes mellitus were excluded for the analyses, to avoid any interferences between medical treatment and biological variables. This resulted in a sample size of 839 subjects (421 mena418 women, age 49.4 AE 8.1 y, body mass index (BMI) 25.7 AE 4.4 kgam 2 ). To evaluate the role of the Pro12Ala polymorphism in the onset of NIDDM, we evaluated its distribution in 170 Caucasian NIDDM subjects from a clinical series (117 mena53 women, age 62.3 AE 9.0 y, BMI 30.1 AE 3.6 kgam 2 ). MEASUREMENTS: The PPARg g2 Pro12Ala polymorphism genotyping was carried out with allele speci®c oligonucleotides hybridisation. Data were statistically analysed for association with various obesity markers (body weight (BW), BMI, waist-to-hip ratio (WHR), plasma leptin concentrations, lipid and glucose variables. RESULTS: In the WHO-MONICA population, the Ala allele frequency was 0.11. The presence of the Ala allele was signi®cantly associated with higher body weight (P 0.002), BMI (P 0.02), height (P 0.02) and waist circumference (P 0.04). Increased plasma concentrations of total cholesterol (P 0.01), LDL-cholesterol (P 0.004) and apolipoprotein B (P 0.01) were also detected in Ala allele bearers. The distribution of the Pro12Ala polymorphism was similar in NIDDM subjects (Ala allele frequency: 0.10) and in the WHO-MONICA population subjects. CONCLUSION: Our results suggest that genetic variability of PPARg g2 affects body weight control and lipid homeostasis in humans and do not support a signi®cant role for the PPARg g2 Pro12Ala polymorphism in the aetiology of NIDDM.
Introduction
Peroxisome Proliferator Activated Receptors (PPARs) are members of the nuclear hormone receptor superfamily. Three subtypes are described: PPARa, PPARd and PPARg, encoded by different genes. PPARs form heterodimers with retinoic X receptors (RXR) and regulate transcription of various genes after binding to PPAR Response Elements (PPREs). PPARg is implicated in adipocyte differentiation 1 ± 3 and regulates lipid and glucose homeostasis. 4, 5 Three different mRNAs of PPARg have been described: ± g1, ± g2 and ± g3, coded by the same gene but resulting of alternate promoter usage and alternate splicing. 6 ± 9 In humans, PPARg1 and PPARg3 proteins are identical whereas PPARg2 differs from ± g1 and ± g3 in a speci®c 28-residue extension at the amino terminus, encoded by a single exon (exon B). PPARg2 is expressed in adipose tissue and liver only, PPARg3 is con®ned to macrophages, adipose tissue and colon epithelium whereas PPARg1 is ubiquitously expressed. 8 ± 10 The hunt for mutations in PPARg gene is of great interest to provide in vivo models helpful to explore the complex biological properties of PPARg. We discovered a silent CaT PPARg polymorphism in exon 6 (common to the three isoforms), whose T allele was associated with elevated plasma leptin levels in obese subjects. 11 A proline to alanine substitution has also been detected in codon 12 of exon B, the speci®c exon of the PPARg2 isoform. 12 ± 17 The Pro12Ala polymorphism has been inconsistently associated with body mass index (BMI) variations 15, 16 and non-insulin dependent diabetes mellitus (NIDDM). 15, 17 Therefore, we sought to explore the in¯uence of the PPARg2 Pro12Ala polymorphism on various clinical and biological variables in a representative sample of 839 French subjects. We also investigated the distribution of this polymorphism in 170 patients suffering from NIDDM diagnosed according to WHO criteria.
Research design and methods

MONICA study
Within the framework of the WHO-MONICA (Multinational MONItoring of trends and determinants of CArdiovascular diseases) project, 18, 19 we constituted in 1995 ± 1997 a representative sample of 1195 men (n 601) and women (n 594) living in the urban community of Lille (northern France), aged 35 ± 64 y. This study was randomly sampled from the electoral rolls, and equally distributed in ten year age classes and gender 11 (overall response rate 77%). To our knowledge, there were no related subjects in our sample. This study was approved by the Ethics Committee of the Centre Hospitalier et Universitaire de Lille. Each individual signed an informed consent. A detailed questionnaire was ®lled out including alcohol and smoking consumption estimations, and personal medical history. Body mass index (BMI kgam 2 ), waist-to-hip ratio (WHR) and blood pressure (BP) were measured. Genomic DNA was available for 1155 subjects. A group composed of individuals without medical treatment for diabetes mellitus, hypercholesterolemia or hypertension was selected to avoid any interferences between medical treatment and biological variables (n 839, 421 mena418 women, age 49. 4 2 , plasma glucose 9.6 AE 3.6 mmolal). All subjects signed an informed consent. Fasting blood samples were collected for each subject.
Biological measurements
Glucose was measured by the glucose oxidase method (DuPont Dimension, Brussels, Belgium). Plasma insulin was measured by radio-immunoassay (BiInsuline, ERIA Pasteur, Chaska, MN, USA). Plasma total cholesterol and triglyceride levels were measured by enzymatic methods (DuPont Dimension, Brussels, Belgium). Plasma leptin levels were measured by radio-immunoassay (Human leptin RIA kit, WakChemie, Medical GMBH, Germany). Plasma apoB levels were measured by immuno-nephelometry (Behring, Liederbach, Germany).
Genetic analysis
Genomic DNA was extracted from white blood cells as previously described. 20 In the WHO-MONICA population, 1149 subjects have been genotyped (6 could not be genotyped for technical reasons). The primers used to amplify part of exon B of the PPARg2 gene were derived from the genomic sequence. 8 H for the mutant allele (mutation underlined). Membranes were hybridised at 56 C for 1 h, washed twice in 1ÂSSC 10%SDS buffer for 5 min, then in 0.5ÂSSC 10%SDS buffer for 5 min, and ®nally in 0.5ÂSSC 10%SDS buffer at 57 C for 3 min. The mutation creating a Hga I restriction site, we controlled 100 genotypes by Hga I digestion resolved on a 3% agarose gel electrophoresis. To achieve this, 10ml of PCR product were digested by 4U of restriction endonuclease Hga I (New England Biolabs, Ozyme, France) with incubation buffer at 37 C overnight, giving two fragments of 80 bp. We obtained 100% of concordance between the two methods.
Statistical analysis
Statistical analyses were performed with the SAS statistical software, version 6.12 (SAS Institute Inc., Cary, NC). Genotypic and allelic distributions were compared with Pearson w 2 statistical tests. The effect of the Pro12Ala polymorphism on quantitative variables was tested with a multivariate analysis of covariance using a general linear model (proc GLM, Type III SS). Linkage disequilibrium between the Pro12Ala polymorphism and the CaT exon 6 polymorphism was computed. 21, 27 The Pro12Ala polymorphism was introduced as a dichotomous variable in the analyses: subjects carrying at least one Ala allele vs subjects without (dominant effect). Data for insulin, glucose, triglycerides and leptin were Log 10 transformed to normalise their distributions. Statistical signi®cance was considered at the P`0.05 level, and Bonferroni correction for multiple comparisons was used when necessary.
Results
In the WHO-MONICA population study (n 839), the genotypic distribution of the PPARg2 Pro12Ala PPAR g g2 Pro 12Ala polymorphism A Meirhaeghe et al polymorphism was: ProaPro: 78.9% (n 662), ProaAla: 19.5% (n 164), AlaaAla: 1.6% (n 13) (Ala allele frequency: 0.11) ( Table 1) . These distributions were in Hardy ± Weinberg equilibrium. The linkage disequilibrium between the PPARg CaT exon 6 polymorphism and the PPARg2 Pro12Ala polymorphism was 65% (data not shown). For statistical analyses. AlaaAla and ProaAla subjects were grouped and compared to ProaPro subjects to explore the impact of the Ala Allele according to a dominant effect as suggested by the distributions of the variables. No signi®cant interactions between genotypes and gender or obese status could be detected. In the whole population, the Ala allele was signi®cantly associated with higher height ( 2.3 cm, P 0.02), body weight (BW) ( 4.3 kg, P 0.002), BMI ( 2.7%, P 0.02), and waist circumference (WC) ( 3.2 cm, P 0.04) (P-values adjusted on age, gender, plasma insulin levels, alcohol and smoking consumptions) ( Table 2) . Concerning biological variables, an increase in plasma total cholesterol ( 4.5%, P 0.01), LDL-cholesterol ( 8.5%, P 0.0004), and apolipoprotein B ( 8%, P 0.01) concentrations was observed in Ala allele bearers (P-values adjusted on age, gender, BMI, alcohol and smoking consumptions) ( Table 3 ). The effects of the Pro12Ala polymorphism on obesity markers and lipid levels were homogenous both in lean (BMI 25 kgam 2 ) and obese (BMI b 30 kgam 2 ) subjects (data not shown) and both in men and women. Indeed, men carrying at least one Ala allele had statistically signi®cant increase in height, BW, WC, plasma LDL-cholesterol and apolipoprotein B concentrations (Tables 2, 3 ). An increase in BMI ( 2.3%) was also observed, but the difference did not reach signi®cance. In women, plasma total cholesterol concentrations were signi®cantly higher in Ala bearers ( 7%, P 0.01) and the other variables exhibited similar trends as observed in men (weight:
2.4 kg, WC: 1.5 cm, BMI: 3%, LDL-cholesterol: 8% apoB: 7%) (Tables 2, 3). ProaAla and AlaaAla subjects were compared to ProaPro subjects. *P-values were adjusted on age, gender, body mass index, alcohol and smoking consumptions. { P-values were adjusted on age, body mass index, alcohol and smoking consumptions. ProaAla and AlaaAla subjects were compared to ProaPro subjects. *P-values were adjusted on age, gender, insulin levels, alcohol and smoking consumptions. { P-values were adjusted on age, insulin levels, alcohol and smoking consumptions. ns: not signi®cant. Data are n (%) for genotypes and n (frequency) for alleles.
PPAR g g2 Pro 12Ala polymorphism A Meirhaeghe et al
In a clinical series of NIDDM subjects (n 170), the genotype and allele distributions of the Pro12Ala polymorphism ProaPro: 80.0% ProaAla: 20.0% AlaaAla: 0% Ala allele frequency: 0.10) were similar to those of the WHO-MONICA population (Table 1) . In NIDDM subjects, no signi®cant differences could be detected between ProaPro subjects and Ala allele bearers for BMI (29 
Discussion
In our study, the PPARg2 Pro12Ala polymorphism was associated with a signi®cant increase in body weight, height, BMI and waist circumference in a sample of non treated French subjects. These results agree with the work of Beamer et al 16 that reported an association between the Ala allele and higher BW, BMI, and waist circumference in 169 very obese Caucasian subjects. Similar tendencies were found in a cohort of 316 Caucasian lean-to-moderately obese men. 16 In contrast, Deeb et al 15 reported that the Ala allele was associated with lower BMI and an improvement in insulin sensitivity in 333 Finnish nondiabetic subjects. Mori et al 14 found no relation between the Pro12Ala mutation and adiposity, fat distribution or insulin resistance in 215 non-diabetic Japanese men but the frequency of the Ala allele in this population was low (f 0.03) which did not allow powerful statistical analyses. The mechanism explaining the higher BMI among Ala allele bearers is unclear. It seems that some environmental andaor genetic factors may modulate the impact of the PPARg2 Pro12Ala polymorphism on obesity markers in vivo.
Subjects bearing the Ala allele had a lipid atherogenic pro®le (increase in plasma LDL-cholesterol). This result may be linked to previous results showing the role of PPARg in lipid accumulation in different cell types, such as mammary epithelium 23, 24 and in atherogenesis through transcriptional induction of the scavenger receptor CD36. 25, 26 CD36 is expressed in adipose tissue and is directly induced during the differentiation of preadipocytes by PPARg. 27 It is activated by fatty acids and may act as a transmembrane transporter of long-chain fatty acids in adipose tissue. 27 CD36 functions in a feedback loop as a receptor for oxidised LDL in which lipid components of oxidised LDL activate PPARg and thereby induce CD36 expression. 25, 26 Moreover, CD36 is also a high af®nity receptor for the native lipoproteins in vitro 28 and transgenic mice overexpressing CD36 have reduced blood lipids, implicating CD36 in lipid metabolism homeostatis. 29 Therefore, as the PPARg2 Pro12Ala polymorphism is associated with reduced PPARg2 activity, 15 this may have an effect upon the CD36 activity and lead to LDL accumulation among Ala allele carriers.
We previously described the impact of a silent polymorphism (C to T substitution in exon 6) in the PPARg gene in the same population sample. 11 We found that obese T allele bearers had elevated plasma leptin levels and increased leptin-to-BMI ratio compared to obese non-bearers, while no association with BMI, height, weight, WC or plasma cholesterol concentration was observed. The lack of association between the PPARg2 Ala allele and leptin levels may be explained by several hypotheses: (i) although PPARg1 and ± g2 both shared exons 1 ± 6, their pattern of expression is different (mainly adipose tissue for PPARg2, ubiquitous for PPARg1); (ii) their NH 2 -termini being different, biochemical properties may differ; and (iii) linkage disequilibrium between these two polymorphisms exists but is not complete (65%).
Our results do not support a role of the PPARg2 Pro12Ala mutation in the aetiology of type 2 diabetes. In our study, the frequency of the Ala allele was similar in NIDDM subjects (0.10) to the one in the WHO-MONICA population study (0.11). Deeb et al 15 reported that the frequency of the Ala allele was markedly lower in 91 NIDDM Japanese-American patients than in controls, suggesting a protective effect of this allele against NIDDM. Ringel et al 17 did not con®rm this result in 503 NIDDM Caucasian subjects (Ala allele frequency: 0.14) and in 522 IDDM subjects (Ala allele frequency: 0.13). Yen et al 12 observed identical Pro12Ala polymorphism frequency in diabetic Caucasian Americans (0.12) to those in our NIDDM subjects. Therefore, it seems unlikely that PPARg2 is implicated in the onset of NIDDM in Caucasian subjects. Other studies in NIDDM patients of different ethnic origins are needed to elucidate this discrepancy.
In conclusion, carriers of the PPARg2 Ala allele had modi®cations in lipoprotein pro®le and anthropometric measurements. Therefore, our results tend to indicate that PPARg2 is implicated in body weight control and lipid homeostasis in humans. The potential role of this polymorphism on metabolic diseases should be further explored in various populations.
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